# Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

> **NCT04421352** · PHASE1 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Relapsed Small Cell Lung Cancer

## Interventions

- **DRUG:** CS1001

## Key facts

- **NCT ID:** NCT04421352
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-12
- **Primary completion:** 2023-12-22
- **Final completion:** 2023-12-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421352, "Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04421352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*